COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #2 of 63
7/8 Late treatment study
Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint)
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Source   PDF   Share   Tweet
Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin showing a significantly lower mean hospital stay with ivermectin: 7.62 vs. 13.22 days, p=0.00005.
0 of 16 ivermectin patients died vs. 2 of 71 control patients.

Gorial et al., 7/8/2020, retrospective, Iraq, Middle East, preprint, 9 authors, dosage 200μg/kg single dose.
risk of death, 71.0% lower, RR 0.29, p = 1.00, treatment 0 of 16 (0.0%), control 2 of 71 (2.8%).
hospitalization time, 42.0% lower, relative time 0.58, p < 0.001, treatment 16, control 71.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.